Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096420 | 0.95 | MAP4K1 (0.32) | APLNRAURKAAURKBMAP4K1 | |
| SCHEMBL4091392 | 0.89 | AURKA (0.33) | AURKAAURKBROCK2ROCK1MAP4K1 | |
| SCHEMBL4103870 | 0.88 | HRH4 (0.34) | AURKAAURKBMAP4K1 | |
| SCHEMBL4091434 | 0.85 | AURKA (0.36) | AURKAAURKBROCK2ROCK1MAP4K1 | |
| SCHEMBL4096426 | 0.85 | CRHR1 (0.36) | AURKAAURKBMAP4K1 | |
| SCHEMBL4107211 | 0.85 | MAP4K1 (0.34) | AURKAAURKBROCK2ROCK1MAP4K1 | |
| SCHEMBL4107130 | 0.84 | CRHR1 (0.33) | AURKAAURKBROCK2ROCK1MAP4K1 | |
| SCHEMBL4100984 | 0.83 | AURKA (0.32) | AURKAAURKBROCK2ROCK1MAP4K1 | |
| SCHEMBL4090148 | 0.83 | AURKA (0.32) | AURKAAURKBROCK2ROCK1MAP4K1 | |
| SCHEMBL4096030 | 0.83 | AURKA (0.36) | AURKAAURKBMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1903045-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | APLNR 1605/4885AURKA 2870/4885AURKB 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.